Kengreal

Active Ingredient(s): Cangrelor
FDA Approved: * June 22, 2015
Pharm Company: * MEDICINES CO
Category: Blood Thinner (Anticoagulant)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Kengreal Overview

Cangrelor (trade name Kengreal in the US and Kengrexal in Europe) is a P2Y12 inhibitor FDA approved as of June 2015 as an antiplatelet drug[1] for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation.[1] Unlike clopidogrel (Plavix), which is a prodrug, cangrelor is an active drug not requiring metabolic conversion. Poor interim results led to the abandonm...

Read more Kengreal Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Cangrelor

Recent Kengreal Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Kengreal: (2 results)

Sorted by National Drug Code

• 10122-620 Kengreal 50 mg Intravenous Injection, Powder, Lyophilized, for Solution by Chiesi USA, Inc.
• 65293-003 Kengreal 50 mg Intravenous Injection, Powder, Lyophilized, for Solution by The Medicines Company

Other drugs which contain Cangrelor or a similar ingredient: (1 result)

• CANGRELOR